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Abstract— Therapeutic “electroporation” involves 
application of electric fields to target cells/tissues, thereby 
rendering their cell membranes transiently porous, thus 
making feasible the cellular uptake and efficacy of 
previously impermeant and ineffective therapeutic agents. 
The objectives of this research are a) the development of 
flexible electrode arrays for incorporation into microsystem 
endoscopic devices, and b) the assessment of their efficacy 
in delivering selected genetic and pharmaceutical anti-
cancer therapies. Gold electrodes were fabricated on flexible 
polyimide substrates following predictive modeling and 
simulation of electric fields using FEMLAB software. 
Subsequent assessment of electroporation efficiency in-vitro 
involved 1) enumeration of viable tumour cells after 
delivery of electric pulses and exposure to low 
concentrations of bleomycin, otherwise known as 
electrochemotherapy 2) Efficacy of gene delivery by 
detection of emitted green fluorescence by cells after 
electroporation with the pEGFP plasmid and 3) In-vivo 
efficacy of electrochemotherapy in a variety of human solid 
tumour masses in nude mouse models (xenografts). The 
flexible electrode system was found to be successful for 
electrical delivery of plasmids and drugs in-vitro and in-
vivo. We found in-vivo complete regression of prostate, 
colon, oesophageal, and renal cancers with reduced growth 
rates for fibrosarcoma and breast cell lines. These flexible 
electrodes are suitable for electrochemotherapy or gene 
therapy to solid tumours masses and may be fabricated for 
application to the treatment of some cancers in humans by 
transcutaneous or endoscopic delivery systems. 
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I.  INTRODUCTION 
 
Despite their improving success rates, current modalities of 
cancer treatment including surgery, radiotherapy and 
chemotherapy are limited by their lack of efficacy in many 
cancers and by collateral disruption of non target 
physiological functions, tissues and organs. To overcome 
these limitations, current research is directed towards i) 
expanding the application of minimally invasive surgical 
procedures and ii) developing novel medical devices for  
 
precise delivery and uptake of therapeutic agents in target 
tissues.  
Therapeutic “electroporation” involves application of 
electric fields to target cells/tissues, thereby rendering their 
cell membranes transiently porous, thus making feasible the 
cellular uptake and efficacy of previously impermeant and 
ineffective therapeutic agents.  Specifically the membrane 
permeability and cytotoxicity of the normally impermeant 
chemotherapeutic drug bleomycin can be dramatically 
enhanced by electroporation, thus achieving greater 
antitumor efficacy with reduced systemic drug 
concentrations and without the associated collateral injury. 
In clinical trials, this treatment has proved promising in a 
variety of tumour types, such as malignant melanoma, head 
and neck cancers and locally recurrent breast cancers (1, 2).  
Presently, electroporation based therapies are limited to the 
treatment of externally accessible tumours or tissues due to a 
reliance on macro electrodes such as calipers and needles (2, 
3). In this study we describe advances made in the 
development of novel flexible electrode arrays which may 
be modified for the application of electrochemotherapy or 
electrogenetherapy to a diversity of previously inaccessible 
tumours.  
We have designed, fabricated and evaluated novel flexible 
electrode arrays for incorporation into microsystem devices. 
We present results showing the efficacy of these flexible 
electrodes in-vitro and in-vivo suggesting that they may be 
used in conjunction with existing endoscopic based systems. 
Future application of these electrodes in humans might 
include the treatment of foregut cancers which are 
recalcitrant to conventional therapies and have a poor 
prognosis with a current five year survival rate of less than 
10% (4).  
 
II.  METHODOLOGY 
 
Fabrication: 
Gold electrodes were fabricated on flexible polyimide of 
50µm thickness. Biocompatible grade KaptonTM was chosen 
(Figure 2). The polymer was roughened using Argon plasma 
etching. This provided an excellent surface for the adhesion 
of chromium (20 nm) and gold (200 nm) layers that were 
evaporated through patterned stainless steel stencils (Alfa-
Fry Technologies, Ireland) using a Temescal BJD1800I 
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evaporator. Electrode arrays were packaged in a format 
suitable for in vitro and in-vivo studies of electroporation 
efficacy (figure 1).  
 
 
Figure 1. Flexible gold electrodes used in the course of the 
electrochemotherapy experiments. Picture shown here 
demonstrates gold electrodes (A and B) adherent to a 
polyimide as produced prior to mounting on a biopsy jaw. 
 
Cell Tissue Culture: 
Tumour cell lines were grown in culture at 37°C in a 
humidified atmosphere of 5% CO2, in either Dulbecco’s 
Modified Essential Medium (DMEM) or RPMI (Roswell 
Park Memorial Institute), supplemented with 10% iron-
supplemented donor calf serum, 50 µg/ml gentamycin, 300 
µg/ml L-glutamine, and 10 mM HEPES, pH 7.4. Tumour 
cells in tissue culture flasks were dislodged from the surface 
of the flasks by first removing the tissue culture media and 
washing the cells with an equal volume of phosphate 
buffered saline (PBS), cells were then treated with 0.05% 
Trypsin + 0.02% EDTA in PBS and incubated for about 2 
min until cells became rounded and easy to dislodge from 
the flask surface. Tissue culture media was added to the 
harvested cells, and the cell suspensions were centrifuged at 
180=g for 5 min. The cell pellets were then resuspended in 
the supplied medium, and the cell densities of the resulting 
cell suspensions were determined using a hemocytometer. 
All cell densities were determined at this point by visual 
count using a hemocytometer, viable cell counts were 
conducted by using the tryphan blue exclusion assay. 
 
Cell Viability Assay: 
Freshly pelleted tumour cells were resuspended in tissue 
culture medium and viable cell counts conducted using a 
hemocytometer. Cell concentrations of 1 x 105 in 100µl 
were prepared in tissue culture medium. Cells in a total 
volume of 100µl were pipetted onto the flexible electrode 
surface and an electroporation pulse delivered. After 10 
minutes cells were diluted in 900µl of tissue culture 
medium. Six 100µl aliquots were pipetted into six wells of a 
96 well plate, along with control (no cells) samples for 
medium-associated background fluorescence measurement, 
and incubated at 37°C at 5% CO2. Cultures were harvested 
by inverting the plates onto paper towels with gentle blotting 
to remove growth medium without disrupting adherent cells. 
After harvest, each plate was kept at -70°C until the assay 
was completed. Plates were thawed at room temperature, 
and 200 µl of the CYQUANT™ GR dye / lysis buffer 
(Molecular Probes, Netherlands) was added to each sample 
well. The samples were incubated in darkness for 2 to 5 min. 
Sample fluorescence was measured as above, and growth 
curves were plotted as fluorescence versus time. 
 
Tumour induction and monitoring: 
 
We used athymic nude mice for induction of human tumour 
xenografts and BalbC or C3H/Hen for isogeneic tumour 
models. Tumours were induced by injecting 2 × 106 tumour 
cells in 100µl of phosphate buffered saline (PBS) 
subcutaneously into the flank of female mice. When the 
tumours reached approximately 100 mm3 in volume, mice 
were randomly divided into experimental groups and 
subjected to specific experimental protocols (n=6). 
Tumours were measured every 48 hours using a digital 
calliper. Tumour volume, v, was calculated using the 
standard formula v = ab2π/6, where a is the longest diameter 
and b is the next longest diameter perpendicular to a. All 
mice were humanely euthanized when the tumour volume 
reached 2 cm3. 
 
Electrochemotherapy Protocol: 
 
Mice were anaesthetised during all procedures using a 
mixture of halothane and O2. For the ECT, 0.25U bleomycin 
(Blenoxane, Sigma Chemical Co.) in 100µl PBS was 
injected intratumourally. The tumour was grasped 
percutaneously at the opposite margins of the tumour using 
two parallel flexible electrodes (6mm diameter) and their 
distance apart measured using a digital callipers. Good 
contact between the electrodes and the skin was assured by 
means of ultrasound gel (Rich Mar, USA). Electric pulses 
were generated by an electropulsator ECM 2001 (BTX Inc., 
San Diego, CA, USA) and incorporated four electric pulses 
(100µs, 1300 v/cm, 1Hz). In the electrochemotherapy 
protocol, mice were treated with electric pulses immediately 
after bleomycin injection. All treatments were well tolerated 
by the animals. 
 
 
III. RESULTS 
 
Finite element modeling using FEMLAB™ software was 
used to simulate the electric fields generated by the flexible 
electrodes as each of a range of pulse waveforms were 
applied. The electroporation parameters required 
optimization prior to experimental use. The variables 
A B 
analysed included the applied voltage, pulse shape, pulse 
duration, frequency, the total number of pulses applied and 
the pulse type (i.e., monopolar versus bipolar). This 
optimization minimised the number of electrode array 
design options produced as only those most likely to yield 
successful results were fabricated (Figure 1). 
Initially the efficacy of the electrodes were assessed in-vitro 
by electroporation enhancement of the chemotherapeutic 
agent bleomycin. The effect of increasing the electrical field 
and bleomycin concentrations on a human prostate cell line 
are shown below. Cell viability was assessed 24 hours 
relative to control studies (Figure 2). Lower voltages are 
ineffective irrespective of bleomycin concentration 
suggesting  requirement of electroporation for optimal drug 
efficacy. 
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Figure 2. Cells of PC3 – human prostate carcinoma were 
subjected to increasing electric field strengths and increasing 
concentrations of bleomycin with cell viability assessed afer 
24 hours. Note: Higher voltages above 800 v/cm are 
necessary for efficacy of bleomycin indicating the 
requirement for electroporation. 
 
Similar results were obtained from experiments conducted 
on oesophageal, renal, colon, fibrosarcoma, and breast cell 
lines. Additional experiments were performed to optimise 
the electric pulses delivered in terms of pulse length and 
frequency. We found four pulses at 1400v/cm with greater 
than 1µg of bleomycin to effectively kill nearly 90% of 
tumour cells. Additionally, the in-situ cell detection kit 
(Roche, MA, USA) was used to assess apoptosis in cells 
after electrochemotherapy. In all cases greater than 90% of 
the treated cells were apoptotic within six hours of the 
electrochemotherapy. 
In-vivo treatment of the tumours was performed in nude 
mice with the flexible electrodes attached to a biopsy jaw in 
order to demonstrate its suitability for future clinical use. 
Full regression of OE19 tumour xenographs was observed in 
four out of six electrochemotherapy treated oesophageal  
 
 
 
 
Figure 3. Human oesophageal xenograph in an athymic nude 
mouse model - days 0, 2 and 28 after electrochemotherapy. 
Note complete resolution of the tumour at 28 days. 
 
The remaining two nodules were subsequently eliminated by 
repeating the procedure after three weeks (figure 4). 
Similar results were obtained for the prostate, renal, and 
colon tumours. The fibrosarcoma and breast cell lines had 
very aggressive growth rates which were stabilised 
following electrochemotherapy. Although the tumours were 
not eliminated their growth rates did not change in the three 
weeks after therapy. Tumour growth rates were only 
affected in all cases in those treated with 
electrochemotherapy. 
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Figure 4. The effects of bleomycin, electroporation or 
electrochemotherapy on the growth of oesophageal tumour 
xerographs in-vivo (OE19, n=6 per group). Tumours were 
monitored for thirty days after treatment. Note: Responses 
were only obtained in those treated with ECT. 
 
IV. DISCUSSION 
 
The flexible electrodes discussed in this paper provide a 
means to expand the use of electrochemotherapy to solid 
mass tumours normally considered inaccessible to 
conventional surgical therapies. We have shown the flexible 
design of the electrode allows for its deployment to the 
shape or contour of the tumour and is stable at the voltages 
used for multiple treatments. In these experiments the 
electrodes are applied to the skin surface and thus the 
electrical field crosses two layers of skin and the underlying 
tumour tissue. Therapeutic cell injury is confined to the zone 
of bleomycin delivery by direct injection of the drug into the 
tumour. This system may therefore be modified for human 
use in the application of electrochemotherapy to cutaneous 
or surface tumours such as breast, malignant melanoma, 
skin cancer, cutaneous metastases and some sarcoma’s. The 
restrictions on the technique itself are limited to the electric 
field generated as opposed to the chemosensitivity of the 
tumours, as exposure to the electric field universally 
increases the uptake by cells of bleomycin several hundred 
fold.  
We and others have experience in the treatment of cutaneous 
tumours in humans with electrochemotherapy using needle 
electrode. The side effects compared with normal bleomycin 
chemotherapeutic doses are negligible because of its 
inability to enter non-permeabilised cells, and it is 
eliminated predominately by renal excretion within four 
hours. The total procedure itself is completed in a matter of 
minutes and is quite amenable to endoscopic delivery, with 
the electric pulses delivered in a few milliseconds.  
Luminal tumours such as those of the foregut, colon and 
bladder, usually involve ulceration of the surface epithelium 
and thus the electrodes may be applied  onto the cancer. In 
this paper we suggest that mounting flexible electrodes on 
an endoscopic biopsy or pincer system may facilitate 
endoscopically delivered electrochemotherapy or 
electrogenetherapy to such tumours. 
 
V.  CONCLUSION 
 
Flexible electrodes may be fabricated for electroporation 
enhanced delivery of genes and drugs to cells and tissues. 
Successful deployment of these electrodes in endoscopic 
biopsy forceps, suggest that they may be used in minimally 
invasive surgical or endoscopic therapy systems. Most solid 
tumours are responsive to electrochemotherapy. 
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